NCIt definition : A fully human effector-silent Fc immunoglobulin G1 (IgG1) trispecific antibody targeting
the tumor-associated antigens (TAAs) B-cell antigen receptor complex-associated protein
beta chain (CD79b; B-cell-specific glycoprotein B29) and cluster of differentiation
20 (CD20), and the T-cell surface antigen CD3, with potential immunostimulating and
antineoplastic activities. Upon administration, anti-CD79b/CD20/CD3 trispecific antibody
JNJ-80948543 targets and binds to CD79b- and/or CD20-expressing tumor B-cells and
CD3 antigen on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to
CD79b- and/or CD20-expressing tumor B-cells, resulting in CTL-mediated killing of
tumor cells. CD79b, a critical receptor for successful B-cell development and part
of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes
of B-cell lymphomas. CD20 is exclusively expressed on B-cells during most stages of
B-cell development and is often overexpressed in B-cell malignancies.;
Semantic type(s)